Atreca to Present at Two Upcoming Investor Conferences
Stifel Healthcare Conference2019
Tuesday, November 19, 2019
10:55 a.m. EST
New York, NY Evercore ISI HealthCONx Conference
Tuesday, December 3, 2019
10:15 a.m. EST
Live audio webcasts of the presentations can be accessed through the Events & Presentations section of the company's website at ir.atreca.com. Archived replays of the webcasts will be available on the company's website for 90 days following each live presentation.
Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. Atreca’s discovery platform relies on the human immune system to discover unique antibody-target pairs from patients experiencing an active immune response against their tumors. These unique antibody-target pairs represent a potentially novel and previously unexplored landscape of immuno-oncology targets and provide the basis for novel clinical therapeutic candidates such as ATRC-101, the company’s lead clinical candidate. The company expects to file an Investigational New Drug application for ATRC-101 by the end of 2019 and to commence a Phase 1b study in multiple solid tumor types in early 2020. For more information on
Chief Financial Officer
Source: Atreca, Inc.